StockWatch
·

Sigachi Industries Ltd

BSE: 543389

P/L Snapshot

Q1 FY27 · standalone

vs Q3 FY26·vs Q1 FY26
Revenue
98.72
+6.7%-14.1%
Expenditure
90.93
+0.2%-2.3%
Net Profit
6.51
+121.9%+106.6%
OPM %
13.39%
+6.39pp+100.84pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-125.88-56.8112.2681.33150.40Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q1 FY27
Price Chart
Reports

Recovery Narrative Meets Hard Math — Q1 Shortfall Strains FY27 Guidance

capacity-utilization · FY27-guidance · MCC-pricing

Result verdictFollow-upQ1 FY2720 Aug 20266 minPharma & Healthcare

Recovery steady but below plan; capacity math questioned

capacity-utilization · MCC-realization-up · API-ramp

TranscriptDeep diveQ1 FY2720 Aug 20266 minPharma & Healthcare

Sigachi Q1 FY27 consolidated PAT swings to ₹8.1 Cr YoY; adjusted profit down ~59%

pharma excipients · margin compression · one-off base effect

ResultsQ1 FY2713 Aug 20263 minPharma & Healthcare
Latest
Board Meeting13 Aug, 4:13 pm

Sigachi Q1 FY27 consolidated PAT swings to ₹8.1 Cr YoY; adjusted profit down ~59%

Sigachi Industries' consolidated Q1 FY27 (quarter ended June 30, 2026) revenue was ₹121.27 Cr, down 5.4% YoY (from ₹128.25 Cr) and roughly flat QoQ (-0.5% versus ₹121.90 Cr in Q4 FY26). Consolidated profit for the period was ₹8.14 Cr (₹6.76 Cr attributable to shareholders, EPS ₹0.18) against a reported loss of ₹100.97 Cr a year ago — on the surface a turnaround. Standalone PAT was ₹6.51 Cr on revenue of ₹98.28 Cr, EPS ₹0.17. That YoY swing is a base effect, not an operating recovery: the year-ago quarter carried a ₹121.01 Cr one-off exceptional charge (both standalone and consolidated) that pushed it into a large reported loss, while this quarter has no exceptional item. Stripping the one-off from the year-ago base, consolidated PAT was ~₹20.04 Cr a year ago — so like-for-like, this quarter's ₹8.14 Cr profit is down roughly 59% YoY even as the reported number went from loss to profit. The compression shows up on operating margin: EBITDA (PBT before exceptional items plus finance costs and depreciation) was ₹17.52 Cr, a margin of 14.4% of revenue, versus ~21.9% a year ago on the same adjusted basis, and about flat against Q4 FY26's 14.6%. Sequentially, reported PAT rose 6.5% QoQ (₹8.14 Cr vs ₹7.65 Cr), but Q4 FY26 also carried a small ₹1.14 Cr exceptional loss, so the underlying QoQ trend is closer to flat. This lines up with what management flagged on the Q3 FY26 concall (Feb 2026): a slow, gradual recovery, FY27 as 'a year of partial momentum without specific revenue targets,' and a return to 20%+ EBITDA margins pushed out to FY28 — this quarter's flat topline and sub-15% margin are consistent with that cautious framing rather than a beat or a miss. No press release or MD&A commentary accompanied this filing beyond the bare BSE outcome letter, so there is no fresh management quote to weigh against the numbers, and a web search turned up no analyst consensus estimates specific to this quarter, so vsStreet is unknown. The quarter's other board actions — approval of the un-audited results, and forfeiture of 3.51 Cr convertible warrants (₹22.88 Cr forfeited) allotted to promoters and investors in August 2023 whose conversion option lapsed unexercised — are capital-structure/governance items unconnected to operating performance. The company's stated near-term catalyst remains commissioning of the 12,000 MTPA MCC and 1,800-ton CCS facility at Dahej, targeted for Q3 FY27, which management calls critical to future growth. Until that capacity comes online, this quarter suggests margin recovery is tracking the cautious FY28 guidance rather than accelerating, and topline growth has yet to show up in the reported numbers.

13 Aug 2026, 04:13 pm

Corporate Events

Board MeetingSIGACHI
2026
15Sep

Board Meeting

The Extra-Ordinary General Meeting will be held to consider …

BSE Filing
Board MeetingSIGACHI
2026
22Aug

Board Meeting

The Board of Directors considered and approved the increase …

BSE Filing
Board MeetingSIGACHI
2026
13Aug

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing
Board MeetingSIGACHI
2026
27Jul

Board Meeting

The meeting of the Board of Directors is scheduled to be hel…

BSE Filing
Board MeetingSIGACHI
2026
30May

Board Meeting

The board meeting is scheduled to consider and approve the s…

BSE Filing
Board MeetingSIGACHI
2026
14Feb

Board Meeting

Standalone and Consolidated Unaudited Financial Results for …

BSE Filing
Board MeetingSIGACHI
2025
24Oct

Board Meeting

Considering and approving the Standalone and Consolidated Un…

BSE Filing
Board MeetingSIGACHI
2025
25Jul

Board Meeting

Standalone and Consolidated Unaudited Financial Results for …

BSE Filing
Board MeetingSIGACHI
2025
3Apr

Board Meeting

Consider and approve the audited Financial Results for the q…

BSE Filing
Board MeetingSIGACHI
2025
1Jan

Board Meeting

Board Meeting

BSE Filing
Board MeetingSIGACHI
2024
13Nov

Board Meeting

Standalone and Consolidated Unaudited Financial Results for …

BSE Filing
Board MeetingSIGACHI
2024
8Nov

Board Meeting

Standalone and Consolidated Unaudited Financial Results for …

BSE Filing
Board MeetingSIGACHI
2024
30Aug

Board Meeting

Allotment of equity shares of Re 1/- each upon conversion of…

BSE Filing
Board MeetingSIGACHI
2024
19Jan

Board Meeting

Consideration and approval of un-audited financial results f…

BSE Filing
Board MeetingSIGACHI
2023
14Nov

Board Meeting

Un-audited Financial Results for the quarter and half-year e…

BSE Filing
Stock SplitSIGACHI
2023
9Oct

1:10

BSE Filing
Board MeetingSIGACHI
2023
9Oct

Board Meeting

Consider and approve the following: Allotment of Equity Shar…

BSE Filing
Board MeetingSIGACHI
2023
9Sep

Board Meeting

Appointment of Statutory Auditor to fill casual vacancy Any …

BSE Filing